Business Wire

STATS Enables New Levels of Football Analysis with Its Newest AI-Powered Solution

25.7.2017 10:30 | Business Wire

Jaa

STATS, the global leader in sports data and intelligence, has launched an innovative new product, STATS Edge. STATS Edge is a search and analytics application powered by artificial intelligence that enables football teams to instantly find video clips and analyse complex patterns in a game with more speed and accuracy than ever before. With the power of AI-driven analytics at their fingertips, analysts can instantly and effectively assess in detail a team’s strengths and weaknesses while focusing on various aspects of the game.

Drawing on STATS’ rich history in data collection and analysis, STATS Edge will utilise data from the Premier League, Championship, La Liga, Ligue de Football Professionnel, Serie A, Bundesliga, Qatar Stars League, Champions League and more. STATS Edge will initially be available in five languages.

STATS Edge unifies football data and video through an easy-to-use and intuitive user interface, developed in close partnership with top English, French and Spanish clubs through a design-thinking methodology. This allows everyone in the football club – from match analysts to the manager – to analyse, annotate and share insights on the same platform.

“It’s increasingly difficult for clubs to process and analyse all the relevant data points available and distil complex information into timely, accurate insight,” said Kenneth Fuchs, STATS’ CEO. “On top of that, traditional analytics don’t always speak the visual language of players and coaches. We’ve applied computer vision and artificial intelligence to bring new levels of context and efficiency to teams already using video for their match preparations. It’ll save them time, allow them to develop proprietary results, and help get them the information to make, share and track the best decisions.”

The STATS Edge search engine allows managers and analysts to use their football vocabulary within a search box to find relevant video clips in seconds across entire leagues or competitions, regardless of the complexity of their queries. They can link a multitude of events and playing styles to search, which allows the execution of more than 1,000 search combinations.

The ability to search across players, teams, styles, set plays and more using natural language is a substantial step forward in accessing complex tracking data in a simple interface. For example, STATS Edge lets users quickly find and retrieve all of a team’s counter attacks which led to goals, a player’s key events such as shots or crosses in the last five games, or passes into a custom defined zone on the pitch. This use of analytics also helps clubs assess the value of a transfer target in order to reach a fully informed decision before making an investment.

Once clips are identified, STATS’ proprietary Exemplar Search, built by its award-winning data science team, can instantly find clips of similar plays at the click of a button. By using AI algorithms, the platform reads the combination of player and ball trajectories as well as events in any clip to retrieve the respective Exemplar Search results.

STATS Edge further builds on the power of AI to provide exciting and intuitive analytical features, starting with set plays and transitions. By dynamically specifying a zone on the field and other variables, the manager and analyst instantly accesses in-depth analysis and all corresponding videos. For example, in set-play analysis of an opponent, one can identify target zones and link them to the most dangerous players and their shooting or goal efficiency. In transition analysis, one can analyse the key players involved, as well as their most typical behaviour after winning or losing the ball.

About STATS

STATS is the global leader in sports intelligence. Trusted by the world’s most innovative teams, leagues and brands seeking the winning edge at the intersection of sports and technology, STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customisable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry today to enhance both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSInsightsUK.

Contact information

STATS
Dennis Dougherty, 847-583-2680
ddougherty@stats.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25Tiedote

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00Tiedote

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03Tiedote

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00Tiedote

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08Tiedote

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00Tiedote

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme